GERN
Geron Corporation [GERN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GERN Stock Summary
In the News
GERN Financial details
Company Rating
-
Market Cap
2.14B
Income
-184.08M
Revenue
237K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
141
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-11.77
Forward P/E
-
PEG
9.57
P/S
9031.79
P/B
8.73
P/C
-
P/FCF
-12.75
Quick Ratio
3.11
Current Ratio
3.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-
EPS this Y
-13.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.61%
Revenue last 5Y
-12.42%
Revenue Q/Q
-85.98%
EPS Q/Q
13.07%
-
-
-
-
SMA20
-0.74%
SMA50
17.39%
SMA100
-4.93%
Inst Own
-
Inst Trans
-
ROA
-47%
ROE
-63%
ROC
-0.68%
Gross Margin
-12640%
Oper. Margin
-81833%
Profit Margin
-77671%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.64-4.05
52W High
-66.75%
52W Low
+33%
RSI
49.08
Rel Volume
0.76
Avg Volume
12.2M
Volume
9.24M
Perf Week
1.53%
Perf Month
-2.21%
Perf Quarter
-4.32%
Perf Half Y
15.65%
-
-
-
-
Beta
0.608
-
-
Volatility
0.03%, 0.03%
Prev Close
-3.62%
Price
1.33
Change
-1.48%
Company Profile
- Volume Average 12.2M
- Market Capitalization 2.14B
- Employee 141
- CEO Dr. John A. Scarlett M.D.
- Headquarters Foster City,CA,US
- IPO Date 1996-07-31
-
Website
https://www.geron.com 
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
